NCT02202759View on ClinicalTrials.gov

A Study of MLN0264 in Participants With Cancer of the Stomach or Gastroesophageal Junction

PHASE2TerminatedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

August 4, 2014

Primary Completion Date

January 15, 2016

Study Completion Date

January 15, 2016

Conditions
Adenocarcinoma of the StomachGastroesophageal Junction Expressing Guanylyl Cyclase C
Interventions
DRUG

MLN0264

MLN0264 IV infusion

Trial Locations (17)

Unknown

Aurora

St. Petersburg

Tampa

Boston

Cincinnati

Nasheville

Nashville

Bruges

Brussels

Leuven

Barcelona

Madrid

Málaga

Seville

London

Manchester

Sutton

Sponsors
All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY

NCT02202759 - A Study of MLN0264 in Participants With Cancer of the Stomach or Gastroesophageal Junction | Biotech Hunter | Biotech Hunter